State Street
HUMA icon

State Street’s Humacyte HUMA Stock Holding History

State Street’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$658K Sell
842,537
-2,201,392
-72% -$2.04M ﹤0.01% 3527
2026
Q1 		$1.85M Buy
3,043,929
+206,653
+7% +$215K ﹤0.01% 3320
2025
Q4 		$2.73M Buy
2,837,276
+429,233
+18% +$608K ﹤0.01% 3236
2025
Q3 		$4.19M Sell
2,408,043
-1,983,068
-45% -$3.89M ﹤0.01% 3058
2025
Q2 		$9.18M Buy
4,391,111
+125,144
+3% +$240K ﹤0.01% 2654
2025
Q1 		$7.27M Sell
4,265,967
-344,529
-7% -$1.29M ﹤0.01% 2718
2024
Q4 		$23.3M Sell
4,610,496
-153,659
-3% -$760K ﹤0.01% 2141
2024
Q3 		$25.9M Buy
4,764,155
+1,895,529
+66% +$12.5M ﹤0.01% 2064
2024
Q2 		$13.8M Buy
2,868,626
+1,655,896
+137% +$8.62M ﹤0.01% 2368
2024
Q1 		$3.77M Buy
1,212,730
+59,939
+5% +$202K ﹤0.01% 3042
2023
Q4 		$3.27M Buy
1,152,791
+26,713
+2% +$68.6K ﹤0.01% 3133
2023
Q3 		$3.3M Buy
1,126,078
+86,798
+8% +$287K ﹤0.01% 3117
2023
Q2 		$2.97M Buy
1,039,280
+378,485
+57% +$1.36M ﹤0.01% 3234
2023
Q1 		$2.04M Buy
660,795
+169,810
+35% +$483K ﹤0.01% 3337
2022
Q4 		$1.04M Buy
490,985
+72,372
+17% +$220K ﹤0.01% 3544
2022
Q3 		$1.36M Buy
418,613
+571
+0.1% +$2.19K ﹤0.01% 3523
2022
Q2 		$1.34M Buy
418,042
+176,839
+73% +$983K ﹤0.01% 3576
2022
Q1 		$1.7M Buy
241,203
+171,526
+246% +$999K ﹤0.01% 3629
2021
Q4 		$505K Buy
+69,677
New +$689K ﹤0.01% 4022

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street's HUMA Position: Q2 2026 in Review

State Street reduced its Humacyte (HUMA) stake by 72% in Q2 2026, selling an estimated $2.04M and leaving 842,537 shares worth $658K. The position accounts for ﹤0.01% of the portfolio, ranked #3527.

State Street first reported a position in HUMA in Q4 2021 and has held it in 19 quarters since. The position peaked at $25.9M in Q3 2024. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • State Street held 842,537 shares of Humacyte worth $658K as of Q2 2026.
  • State Street sold 2,201,392 Humacyte shares in Q2 2026, an estimated $2.04M.
  • Humacyte made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3527 holding.
  • State Street first reported a position in Humacyte in Q4 2021 and has held it in 19 quarters since.
  • State Street's Humacyte position peaked at $25.9M in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.